Kornimate/medical-research-clean huggingface dataset:
diagnostic study of gene alterations in patients with acute myeloid leukemia

Conditions: Leukemia

Summary: rationale: diagnostic procedures, such as genetic testing, may improve the ability to detect acute myeloid leukemia and determine the extent of disease. purpose: diagnostic study to try to detect changes in the genes of patients who have acute myeloid leukemia.

objectives: * determine the frequency of partial tandem duplication of all1 (mll) in patients with acute myeloid leukemia (aml). * determine the predictive value of partial tandem duplication of all1 to identify a subset of aml patients who have a short duration of complete remission. outline: all samples are obtained from specimens collected on calgb-9665. no additional blood or bone marrow samples are collected. samples are examined by southern blot analysis for gene rearrangement at 11q23. samples showing evidence of all1 gene rearrangement are further analyzed by reverse transcription pcr amplification and/or cytogenetic analysis to detect partial tandem duplication of all1.

Eligibility criteria:
disease characteristics: * prior registration on protocol calgb-9665 * diagnosed with acute myeloid leukemia (aml) * treated on a calgb aml treatment protocol * diagnostic bone marrow or blood specimen available patient characteristics: age: * 15 and over

Keywords: recurrent adult acute myeloid leukemia adult acute myeloid leukemia in remission
parental knowledge, attitude and practice towards oral health of their children

Conditions: Dental Caries

Summary: the aim of this study is to assess the parental knowledge, attitude and practice towards oral health of their children in relation to caries experience.

primary teeth are important as much as permanent teeth. dental plaque is considered the major cause of dental diseases, it begins to adhere to the teeth after eruption. therefore, regular dental care for children becomes essential. children at preschool age lack the awareness of primary teeth importance, the knowledge in dental health care and the ability to maintain adequate oral health. hence, it is the parents' responsibility to take care of their children's teeth in collaboration with dentists and their advices. a good understanding of the parental knowledge, attitudes, beliefs and awareness regarding oral health is essential for the effectiveness of oral health promotion efforts aim at improving the dental health of young children. it has been found that the more positive the attitude of parents is towards dentistry; the better their children's dental health status. children from low-income and underprivileged families have been found to have high caries prevalence and poor oral health. therefore, it is important to assess the knowledge and attitude of parents, as their behaviour towards their children oral health is of a huge impact. this may also have implications on early dental visits aimed for prevention rather than restorative treatment. so, parents' knowledge and attitude have a significant influence on the children's dental and gingival health. lack of parental knowledge and positive attitudes regarding primary teeth create barriers to early preventive dental care. in addition, studying and understanding parental dental knowledge and attitude would be of a good help in effective planning for well-targeted dental health promotional campaigns by shedding the light on the knowledge gaps and negative attitudes of the parents regarding dental health

Eligibility criteria:
inclusion criteria: * parents of children with primary dentition. exclusion criteria: * parents of children with psychological problems. * parents of children with chronic illness. * parents who refuse to participate.
the role of microrna in the diagnosis, prognosis and response to treatment in pancreatic cancer

Conditions: Pancreatic Cancer Stage III; Pancreatic Cancer Stage IV; Pancreatic Ductal Adenocarcinoma; Pancreatic Neoplasms

Summary: aberrant mirna production has been linked to a wide range of human cancers and shown to play important roles in their genesis and growth. these mirna can be detected in the blood and tumors of patients with cancer. the investigators hypothesize that the detection of certain mirnas present in the blood/serum of patients with pancreatic cancer may be important to the early diagnosis of the disease. furthermore, the investigators hypothesize that mirna detection in pc patients will yield prognostic information and help predict the response to treatment.

specific aims of the study include: 1. to obtain serum samples from patients with newly diagnosed pancreatic cancer at baseline before treatment and monthly throughout treatment. 2. to analyze the mirna profiles present at each time point. 3. to determine mirnas that may distinguish pancreatic patients from unaffected individuals. this could be developed into a diagnostic test. 4. to determine mirnas whose levels correlate with treatment response, both in patients with and without elevations in the serum tumor marker ca 19-9.

Eligibility criteria:
inclusion criteria: * have biopsy proven adenocarcinoma of the pancreas * have initially inoperable disease, classified as either locally advanced or metastatic disease * recurrent disease after a whipple procedure is allowed * patients who are able to undergo resection after neoadjuvant therapy will continue to be followed after resection * have radiographically measurable disease * have an ecog performance status of 2 or less * be willing to contribute the required information and specimens * provide written signed consent to participate exclusion criteria: * having received prior anti-cancer treatments for metastatic pancreatic cancer * concurrently receiving systemic therapy for another cancer except androgen deprivation therapy for stable/controlled prostate cancer * presence of other active cancer except for: adequately treated local basal or squamous cell carcinoma of the skin, cervical carcinoma in situ, superficial bladder cancer, asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy or requiring only hormonal therapy and with normal prostate-specific antigen for \>1 year prior to start of trial. other adequately treated stage 1 or 2 cancer currently in complete remission, or any other cancer that has been in complete remission for \> 5 years is allowable

Keywords: pancreas cancer biomarker
a study to investigate vamikibart (ro7200220) in diabetic macular edema

Conditions: Diabetic Macular Edema

Summary: study bp43445 is a phase ii, multicenter, randomized, double-masked, active comparator-controlled study to investigate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of vamikibart administered intravitreally in participants with diabetic macular edema. only one eye will be chosen as the study eye. the duration of the study will be up to 76 weeks.


Eligibility criteria:
inclusion criteria: * diagnosis of diabetes mellitus (type 1 or type 2) * macular thickening secondary to diabetic macular edema (dme) involving the center of the macula * decreased visual acuity attributable primarily to dme * ability and willingness to provide written informed consent and to comply with the study protocol * willingness to allow aqueous humor collection * for women of childbearing potential: agreement to remain abstinent or use at least one highly effective contraceptive method that results in a failure rate of \<1% per year during the treatment period and for at least 12 weeks after the final dose of study treatment exclusion criteria: * hemoglobin a1c (hba1c) of greater than (\>) 12% * uncontrolled blood pressure, defined as a systolic value greater than (\>)180 millimeters of mercury (mmhg) and/or a diastolic value \>100 mmhg while a patient is at rest * currently pregnant or breastfeeding, or intend to become pregnant during the study * prior treatment with panretinal photocoagulation or macular laser to the study eye * any intraocular or periocular corticosteroid treatment within the past 16 weeks prior to day 1 to the study eye * prior iluvien or retisert implants within 3 years prior to day 1 to the study eye * prior or concomitant treatment with anti-vegf therapy within 8 weeks prior to day 1 to the study eye; vabysmo\^tm within 16 weeks prior to day 1, prior beovu® is not permitted * prior administration of ivt brolucizumab (beovu®): ever; vamikibart: \</=24 weeks prior to day 1) in either eye * any proliferative diabetic retinopathy * active intraocular or periocular infection or active intraocular inflammation in the study eye * any current or history of ocular disease other than dme that may confound assessment of the macula or affect central vision in the study eye * any current ocular condition which, in the opinion of the investigator, is currently causing or could be expected to contribute to irreversible vision loss due to a cause other than dme in the study eye * other protocol-specified inclusion/exclusion criteria may apply
influence continuous veno-venous hemodialysis the autoregulation

Conditions: Acute Renal Failure

Summary: the aim of the study is to characterize the influence of continuous veno-venous hemodialysis on the cerebrovascular autoregulation.

patients at the intensive care unit who suffered acute renal failure with the need of continuous veno-venous hemodialysis will be investigated with continuous veno-venous hemodialysis and in a time window without continuous veno-venous hemodialysis to investigate the influence of continuous veno-venous hemodialysis on the cerebrovascular autoregulation.

Eligibility criteria:
inclusion criteria: * acute renal failure * need for continuous veno-venous hemodialysis * age \>18 years exclusion criteria: * sepsis * preexisting cerebral illness * traumatic brain injury * meningitis or encephalitis * pregnancy

Keywords: acute renal failure cerebrovascular autoregulation transcranial doppler continuous veno-venous hemodialysis
booster dose of hcg for unruptured follicle in non ivf/icsi cycles

Conditions: LUF - Luteinised Unruptured Follicle Syndrome

Summary: this study will be conducted to assess the effect of booster dose of hcg on the unruptured follicles in non ivf/icsi cycles.

in this study enrolled patients (n=160) who underwent controlled ovarian stimulation and timed intercourse with unruptured mature graffian follicle 48 hours after im 10,000 iu hcg dose. patients were allocated randomly into intervention group and control group. in the intervention group another booster dose (10,000 iu of hcg) was given im while in the control group 2 ml normal saline was given im leaving follicles for spontaneous rupture

Eligibility criteria:
inclusion criteria: * ordinary stimulated cycles * iui stimulated cycles * unruptured follicle after 10000 iu im hcg triggering exclusion criteria: * ivf/icsi cycles

Keywords: luf hcg booster dose ovulation rate pregnancy rate
characterisation of asthma in obese subjects

Conditions: Asthma; Obesity

Summary: our hypothesis: obese subjects with a physician's made diagnosis of asthma have a poorer asthma control than asthmatics with normal weight, less variability of peak expiratory flows (pef) and bronchodilator response,increased induced sputum and systemic markers of inflammation and an increased prevalence of atopy. obese subjects have an increased incidence of co-morbidities such as rhinosinusitis, gastroesophageal reflux and sleep apnea syndrome. this study aims to determine if, in comparison with asthmatics with a normal weight, paired for age and sex, obese subjects with asthma (all not using anti-inflammatory agents) show: * a more uncontrolled asthma, increased health care use and poorer quality of life * a reduced response to bronchodilators and diurnal variability of expiratory flows * more marked airway inflammation and evidences of a systemic inflammatory response * an increased prevalence of co-morbidities which can influence the report of respiratory symptoms or the severity of the disease, such as esophageal reflux symptoms, upper airway disease (rhinitis) and sleep apnea syndrome or other sleep disorder.

questionnaires on respiratory symptoms, health care use, quality of life, medication and asthma control will be administered and a thoracic examination performed. spirometry and bronchodilator response, blood tests for inflammatory parameters, ph measurements in exhaled air condensate and sputum induction will be performed. peak expiratory flows will be measured and recorded on a diary card during one week. on the second visit, measures of lung volumes and a methacholine challenge will be performed.

Eligibility criteria:
inclusion criteria: * aged 18 and over. * in good health apart from asthma or obesity as determined by history and physical examination (no other condition which could influence the proposed tests). * all will be non smokers or ex- smokers for more than six months with a smoking history of no more than 10 pack- years (i.e., one pack per day or its equivalent for 10 years.) * subjects will have a physician's made diagnosis of asthma and have received a bronchodilator prescription in the last year. exclusion criteria: * use of asthma medications other than bronchodilators * subjects who are, in the opinion of the investigator, mentally or legally * incapacitated thus preventing informed consent from being obtained. * subjects having a co-existing illness that precludes them from the trial. * pregnancy or lactation
zostavax® at minimum release specification approaching expiry (v211-044)

Conditions: Herpes Zoster

Summary: primary objective: to demonstrate whether or not zostavax® at minimum release specification approaching expiry potency elicits an acceptable varicella-zoster virus (vzv) antibody fold rise (measured by glycoprotein enzyme linked immunosorbent assay \[gpelisa\]) from pre-vaccination to 4 weeks post-vaccination. secondary objectives: to describe the safety profile of zostavax® at minimum release specification approaching expiry potency.


Eligibility criteria:
inclusion criteria: * participant of either gender aged ≥50 years * positive history of varicella or residence for \>30 years in a country with endemic vzv infection * all females must be postmenopausal or have a negative serum or urine pregnancy test or acceptable method of birth control for three months after vaccination * participant having signed the informed consent form prior to any study procedure exclusion criteria: * febrile within 72 hours prior to vaccination * prior history of herpes zoster clinically diagnosed by a physician * previously received a varicella or zoster vaccine * exposure to varicella or herpes-zoster within 4 weeks prior to vaccination * received any other live virus vaccine within 4 weeks prior to vaccination, or is expected to receive any other live virus vaccine during the study * received any inactivated vaccine within 2 weeks prior to vaccination, or is expected to receive any inactivated vaccine during the study * was treated with immunoglobulins or any blood products, other than autologous blood transfusion, given during the 5 months prior to vaccination or is expected to be treated during the study * taking any non topical antiviral therapy with activity against herpesviruses. * on immunosuppressive therapy * known or suspected immune dysfunction caused by a medical condition, or any other cause * history of hypersensitivity reaction or anaphylactoid reaction to any vaccine component, including gelatin or neomycin * known active tuberculosis * significant underlying illness preventing completion of the study
the no-als study: a trial of nicotinamide/pterostilbene supplement in als.

Conditions: Amyotrophic Lateral Sclerosis

Summary: amyotrophic lateral sclerosis (als) is a serious rapidly progressive disease of the nervous system. the average survival from the time of diagnosis is 3 years. apart from riluzole, there is no effective treatment. care of advanced als will have a cost of 4-8 million nok per year research i.a. from the investigators department has shown that increased activity in histone deacetylation enzymes (sirtuins) together with increased access to nad can delay disease progression. nicotinamide riboside (nr) can increase cells' access to nad and pterostilben will stimulate sirtuins. the investigators want to study whether combination therapy with nr and pterostilben can inhibit neurodegeneration in als and thereby delay disease development, increase survival and improve quality of life in als. in the study, the investigators will use 2 different dosages on the active treatment and strength calculations show that 180 patients are needed to show a rather weak effect. patients will be recruited in collaboration with hospitals in helse vest, ahus, drammen, ous and st. olavs hospital.


Eligibility criteria:
inclusion criteria: arm 1 (newly diagnosed als patients) * have a clinical diagnosis of probable als according to the revised el escorial criteria. * mr of the brain and cervical spine cannot explain symptoms. * diagnosed with likely als within 6 months from enrolment and treated with riluzole 50mg x 2 * symptom onset no longer than 2 year prior to inclusion. * als-frc-r of 36 or more (not any item below 2). * age equal to or greater than 35 years at time of enrollment arm 2 (earlier diagnosed als patients) * have a clinical diagnosis of probable als according to the revised el escorial criteria. * mr of the brain and cervical spine cannot explain symptoms. * treated with riluzole 50mg x 2. exclusion criteria: * dementia, ftd or other neurodegenerative disorder at baseline visit * any psychiatric disorder that would interfere with compliance in the study. * use of high dose vitamin b3 supplementation within 30 days of enrollment * metabolic, neoplastic, or other physically or mentally debilitating disorder at baseline visit. * genetically confirmed mitochondrial disease * patients who become tracheostomized as part of the treatment of als * patients with short expected survival at the discretion of the investigator. such cases cannot be expected to follow protocol procedures.
development of neuro-navigated transcranial magnetic stimulation (tms) using mri

Conditions: Treatment Resistant Depression

Summary: healthy controls (hc) will be studied once to provide data needed to validate the virtual neuro-navigation system. all subjects will undergo a single mri session and will then participate in an on-line neuro-navigation session in which various tms coil positions will be recorded. the brain/head images will be provided to the programmer to permit development of the virtual neuro-navigation algorithm. data from yr1 will be used by the programmer as a training sample, and from yr2 as a test sample.

hc subjects (n=10)/yr will be studied once to provide data needed to validate the virtual neuro-navigation system. all subjects will undergo a single human connectome project compatible mri session permitting application of both surface-based and more standard volumetric analyses. subjects will then participate in an on-line neuro-navigation session in which tms coil positions (in 10/20 coordinate space) will be recorded corresponding to the following targets: 1) hand-representation of motor strip; 2) 5-cm location; 3) 5.5 cm location; 4) mni coordinates corresponding to the "fitzgerald"4 and "weigand"6 volumetric targets; 5) peak anti-correlated region (calculated from rsfcfmri data alone); 6) center of our targeted parcel, calculated using surface-based approaches. the brain/head images will be provided to the programmer to permit development of the virtual neuro-navigation algorithm. data from yr1 will be used by the programmer as a training sample, and from yr2 as a test sample. the go/no-go criterion is an interclass correlation coefficient (icc) of \>.9 between scalp coordinates determined by on-line neuro-navigation and those determined virtually

Eligibility criteria:
inclusion criteria: * non-depressed subjects exclusion criteria: * ever met criteria for a psychotic disorder (sz, szaff, bipolar disorder); anorexia nervosa or bulimia nervosa within the last year * unstable medical condition by history, physical exam or laboratory results * contraindications to mri (based on metal screening form) * meets criteria for claustrophobia * recent drug or alcohol use disorder with dsm-5 specifier of moderate or severe within 6 months, or mild within 2 months; lifetime history of iv drug use * a neurological or neuromuscular disorder; * require medications for a general medical condition that contraindicate the tms treatment * history of ketamine treatment within 6 mo * history of monoamine oxidase inhibitor (maoi) within the past month * lacks capacity to consent * taking medications that increase the risk of seizures. for patients on permitted concomitant psychotropic agents (antidepressants, anticonvulsants, benzodiazepines, hypnotics, opiates, triiodothyronine (t3), modafinil, psychostimulants, buspirone, melatonin, omega-3 fatty acids, folate, lmethylfolate, s-adenosyl methionine, lithium) dosing must be stable for at least four weeks prior to study entry
exercise protocols in postural balance of elderly women

Conditions: Sarcopenia

Summary: to determine and compare the effects of a training program with pilates and facilitation neuromuscular proprioceptive on balance and function in elderly women.

older women living in teresina and participating in a local church project called "pão dos pobres" were randomly divided into three groups: proprioceptive neuromuscular facilitation (pnfg), pilates (pg) and control(cg). intervention: a training program (50 minutes session) was performed with the pnfg and the pg, 3 times a week, for 4 weeks. the elderly in cg suffered no intervention and continued with their daily activities. main outcome measures: the stabilometric parameters, berg balance scale score, functional reach test and timed up and go test (tug test) were measured before and one month after, in all participants.

Eligibility criteria:
inclusion criteria: * all the subjects were between 60 and 80 years old, * sedentary and healthy exclusion criteria: -orthopedic, cardiovascular, vestibular, psychological, neurological or any other impairment that would not allow the execution of all study tasks

Keywords: physical activity rehabilitation older adults pilates proprioceptive neuromuscular facilitation